Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL901663 | 0.84 | ADAMTS5 (0.38) | USP30MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL12266239 | 0.84 | CYP11B2 (0.46) | MAPTMEN1TSHRKMT2A | |
| SCHEMBL521045 | 0.83 | GPR119 (0.51) | GPR119USP30MAPTALDH1A1LMNA | |
| SCHEMBL29384737 | 0.83 | GPR119 (0.51) | GPR119USP30MAPTALDH1A1LMNA | |
| SCHEMBL247897 | 0.83 | MAPT (0.59) | GPR119USP30MAPTALDH1A1LMNA | |
| SCHEMBL3758659 | 0.83 | MAPT (0.46) | GPR119USP30MAPTALDH1A1LMNA | |
| SCHEMBL12205269 | 0.82 | GPR119 (0.56) | GPR119MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL15753879 | 0.82 | MAPT (0.47) | GPR119USP30MAPTALDH1A1LMNA | |
| SCHEMBL24723111 | 0.81 | USP30 (0.44) | GPR119USP30MAPTALDH1A1LMNA | |
| SCHEMBL1075234 | 0.81 | USP30 (0.53) | GPR119USP30MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325908-B2 | CaMKII inhibitors and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3189052-B1 | CAMKII INHIBITORS AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20200385383-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10759792-B2 | CaMKII inhibitors and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-2952510-B1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2018-12-26 | — | — | EP | disclosed |
| US-20170247374-A1 | CaMKII INHIBITORS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| US-20170247374-A1 | CaMKII INHIBITORS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| US-9708295-B2 | Substituted 2-aminopyridine protein kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-07-18 | — | — | US | disclosed |
| WO-2016037106-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC (US) | 2016-03-10 | — | — | WO | disclosed |
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| EP-2717694-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Limited (GB) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012170752-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170752-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-12-13 | — | — | WO | disclosed |
| EP-2441755-A1 | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors | Almirall, S.A. (ES) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012041476-A1 | PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325908-B2 | CaMKII inhibitors and uses thereof | CAMK2G, CAMK2B, CAMK1 | GPR119 2441/4885USP30 2304/4885MAPT 790/4885 |
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | PACSIN2, MAPKAPK2, PRKCA | GPR119 843/4885USP30 3274/4885MAPT 1571/4885 |
| US-20170247374-A1 | CaMKII INHIBITORS AND USES THEREOF | CAMK2G, CAMK2B, CAMK1 | GPR119 2441/4885USP30 2304/4885MAPT 790/4885 |
| US-20140155375-A1 | NOVEL COMPOUNDS | CYBB, NOX1, NOX4 | GPR119 413/4885USP30 2048/4885MAPT 1644/4885 |
| US-20200385383-A1 | CaMKII INHIBITORS AND USES THEREOF | CAMK2G, CAMK2B, CAMK1 | GPR119 2441/4885USP30 2304/4885MAPT 790/4885 |
| US-10759792-B2 | CaMKII inhibitors and uses thereof | CAMK2G, CAMK2B, CAMK1 | GPR119 2441/4885USP30 2304/4885MAPT 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.